Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute, Egypt
Kousai Bio Co., Ltd.
Thomas Jefferson University
Baylor College of Medicine
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
Institute of Hematology & Blood Diseases Hospital, China
The First Affiliated Hospital of Soochow University
Institut Claudius Regaud
Yale University
UNC Lineberger Comprehensive Cancer Center
Fundación de investigación HM
St. Jude Children's Research Hospital
University of Pittsburgh
National Cancer Centre, Singapore
Memorial Sloan Kettering Cancer Center
The General Hospital of Western Theater Command
Global Coalition for Adaptive Research
Hoosier Cancer Research Network
Memorial Sloan Kettering Cancer Center
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Affiliated Hospital to Academy of Military Medical Sciences
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
University of Utah
The First Affiliated Hospital of Soochow University
Medical College of Wisconsin
H. Lee Moffitt Cancer Center and Research Institute
Brown University
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Fudan University
CHU de Quebec-Universite Laval
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Yale University
Fondazione del Piemonte per l'Oncologia
University Health Network, Toronto
Chinese PLA General Hospital
New Approaches to Neuroblastoma Therapy Consortium
University of Pittsburgh
Chang Gung Memorial Hospital
Gruppo Oncologico del Nord-Ovest
UNC Lineberger Comprehensive Cancer Center
Centre Oscar Lambret
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center